Lincoln Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 28, 2026, recommended Final Dividend of Rs. 1.80 per equity share.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals reported FY26 consolidated net profit of Rs. 87.89 crore, up 6.74% from Rs. 82.35 crore in FY25. Revenue from operations grew 9.10% to Rs. 704.48 crore, while EBITDA increased 5.78% to Rs. 131.14 crore. The Board recommended a final dividend of Rs. 1.80 per equity share (18% on face value of Rs. 10), subject to shareholder approval at the upcoming AGM. The company maintained an unmodified audit opinion from statutory auditors. FII holding increased to 5.20% as of March 31, 2026.
The consistent dividend payout signals financial stability and shareholder-friendly approach. The company aims to achieve Rs. 1,000 crore revenue in the next 3 years with 15-18% annual growth, driven by cardiac, diabetic, dermatology, and ENT segments.